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Abstract
Benefits of switching to a single-tablet regimen (STR) of emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) in
virologically suppressed antiretroviral treatment (ART) experienced HIV-positive women include pregnancy
category B rating and lack of clinically significant drug interactions between RPV and oral contraceptives.
Unfortunately, studies involving switching to FTC/RPV/TDF enrolled fewer than 25% women. We undertook
this 48-week study to assess the ability of virologically suppressed HIV-positive women switching to RPV STR
to remain virologically suppressed and comply with the caloric intake requirement. HIV-positive women on
ART with viral load <50 c/mL for 6 months before study entry and no known resistance to FTC, TDF, or RPV
were enrolled and switched to STR RPV/FTC/TDF. Caloric intake (‡400 kcal) compliance and concurrency
with oral STR RPV/FTC/TDF were evaluated with a 3-day food diary, which was validated by obtaining
participant’s caloric consumption through phone calls on randomly chosen dates. For each 3-day food diary, the
daily median caloric intake and median value for each macronutrient consumed concurrent with FTC/RPV/TDF
were computed. Medication adherence was measured using a visual analog scale. We enrolled 33 women, 73%
of whom were African American. At week 48, virologic suppression (HIV RNA <40 c/mL) was maintained in
96% of women, including those (n = 4) who reported imperfect ART adherence. The daily median caloric
intake concurrent with FTC/RPV/TDF was 820 kcal by food diary and 677 kcal by random phone call. Median
kcal intake (food diary) did not change significantly from baseline (684 kcal) to week 48 (820 kcal); median
change 102 kcal, p = .15. Women who reported noncompliance with a ‡400 kcal meal did not experience
virologic failure. Significant concordance between caloric adherence and virologic suppression was not
detected. Our study demonstrated that HIV-positive women who switched to STR FTC/RPV/TDF continued
to experience virologic suppression and were readily able to comply with the recommended caloric intake
requirement.
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Introduction
In December 2013, the United States Food and DrugAdministration approved the use of single-tablet regimen
(STR) of emtricitabine (FTC), rilpivirine (RPV), and teno-
fovir (TDF) as a ‘‘switch’’ regimen for use in HIV+ viro-
logically suppressed adult patients on stable antiretroviral
treatment (ART) regimens. This approval was primarily
based on results from the randomized open-label phase 3b
SPIRIT trial, which demonstrated that switching from a
ritonavir-boosted protease inhibitor (PI) to FTC/RPV/TDF
maintained virologic suppression through week 48.1 Subse-
quently, additional studies demonstrated that switching to
FTC/RPV/TDF from various other ART regimens was both
safe and efficacious.2–4
Considerations for ART regimen switching in the setting
of sustained virologic suppression include the following:
regimen simplification, adverse events associated with the
current regimen, or an enhanced safety profile of the new
regimen. Switching to an RPV-based regimen might prove
beneficial for the following reasons: improved lipid profile,1,2
fewer neuropsychiatric side effects, no clinically significant
drug interactions for patients on methadone therapy, and
small pill size. FTC/RPV/TDF has a pregnancy category B
rating and the lack of clinically significant drug interactions
between RPV and oral contraceptives is a key consideration
when considering switch regimens for women of child-
bearing potential (Edurant [rilpivirine] tablets; Tibotec
Pharmaceuticals, Raritan, NJ).5 Unfortunately, the SPIRIT
study enrolled 14% women, Mills et al. (switching from
efavirenz to RPV) enrolled 8.2% women, and Monczor et al.
enrolled 25% women.1–3 Thus, among women who are likely
to achieve notable benefit, there is limited data on the efficacy
of switching to FTC/RPV/TDF.
While switching to FTC/RPV/TDF appears to be an at-
tractive choice for women, this must be balanced with the
recommended caloric requirement. The complex and multi-
functional roles women must play at work and in the home
influence their ability to put self first. Women are frequently the
primary caregivers and issues related to childcare or eldercare
may limit their ability to focus on their own health needs, and
may influence adherence to specific medication dosing re-
quirements. Regular administration of RPV-based regimens
with food is important, as the absorption of RPV is optimal
when taken with either a normal-fat or high-fat diet. Lower
absorption would likely decrease the effectiveness of RPV in
suppressing HIV replication and could lead to virologic failure.
Therefore, we undertook this 48-week study to assess the abil-
ity of virologically suppressed HIV-positive women switch-
ing to FTC/RPV/TDF to remain virologically suppressed and
comply with the caloric intake requirement, and to study the
agreement between caloric intake and virologic suppression.
Secondary aims were to assess antiretroviral (ARV) treatment
adherence and changes in fasting lipid profile.
Methods
Between April 2012 and April 2014, HIV-positive women
on stable combination ART with viral load <50 copies/mL
for 6 months before study entry and no known resistance to
FTC, TDF, or RPV were enrolled and switched to FTC/RPV/
TDF. All enrolled women received healthcare at the Uni-
versity of North Carolina Infectious Diseases Clinic (UNC ID
Clinic). Resistance was defined as the presence of the nu-
cleoside reverse transcriptase mutations K65R and M184 V/I
and the nonnucleoside reverse transcriptase mutations K101E/
P, E138G/K/Q/R, Y181C/I/V, and H221Y. Viral suppression
was defined as HIV RNA <50 copies/mL and caloric adher-
ence was defined as ‡400 kcal at the meal consumed concur-
rent with FTC/RPV/TDF intake. ARV medication adherence
was measured using a visual analog scale (VAS).
A food diary and phone dietary assessment were used to
measure compliance with caloric intake. All participants were
asked to keep a 3-day food recall diary to collect information
on the following: (1) meal time when FTC/RPV/TDF was
taken, (2) food items consumed at this meal, and (3) bever-
ages consumed at this meal. To avoid response fatigue, par-
ticipants were asked to keep the diary for 2 weeks (weeks 1
and 3 of each month) in months 1–6 and 1 week per month for
months 7–12. The validity of the food diary was assessed by
obtaining participant’s caloric consumption through phone
calls on randomly chosen dates (one per month). During these
calls, participants were asked to recall the (1) meal time when
STR FTC/RPV/TDF was taken, (2) food items consumed at
this meal, and (3) beverages consumed at this meal. As car-
bohydrates from sugar-sweetened beverages (SSB) increase
gastric transit time, we compared consumption of all calories
versus all calories minus SSB.6 A 7-day run-in period from
screening to baseline (week 0) was used to familiarize study
participants with use of the food diary. During the run-in
period, participants did not make any adjustment to dietary
intake and remained on their old ART regimen. Each 3-day
food diary was summarized using the median caloric intake.
Nutrition variables measured included the total caloric intake,
macronutrients (proteins, carbohydrates, and fats), foods
without sugar-sweetened beverages, and foods without any
beverage. Except where stated otherwise, caloric intake
analysis includes all foods and beverages consumed.
Analysis week windows were defined as postentry to <8
weeks for ‘‘week 4’’; 8 to <36 weeks for ‘‘week 24’’; and 36
weeks onward for ‘‘week 48’’. Concurrence between caloric
intake and virologic suppression was obtained by using the
3-day food diary measurement closest to the scheduled HIV
RNA measurement. A kappa coefficient and exact test were
used to evaluate concordance between caloric compliance
(‡400 kcal) and antiretroviral adherence. Changes in caloric
intake, body weight, and fasting lipids, each from baseline to
week 48, were assessed using a Wilcoxon signed-rank test.
Complete case analyses were used (i.e., missing data were
excluded). Nutrition information was summarized using
Food Processor 10.13.1 software. Statistical analyses were
conducted in SAS 9.3 (SAS Institute, Cary, NC).
Results
Of 33 women enrolled in the study, 27 women had an
evaluable HIV-1 RNA measurement, 26 had a random call
caloric measurement, and 21 had a food diary caloric mea-
surement at week 48. One participant who was unable to
attend the week 48 visit was missing HIV-1 RNA, but had
caloric measurements from food diary and random call
available in the week 48 window. Of the six women who
discontinued the study early, only one discontinued due to
ARV failure; other reasons included loss to follow-up (n = 2),
allergic reaction (n = 1), and patient preference (n = 2).
Most participants were African American (73%), median
age was 46 years, and median time since HIV diagnosis
was 13 years (Table 1). At baseline, 88% of participants
were overweight/obese (body mass index ‡25 kg/m2).
Virologic suppression
Virologic suppression was maintained in 100% (n = 31) of
participants at week 4; 97% (29/30) of participants at week
24; and 96% (26/27) of participants at week 48. The one par-
ticipant with ARV treatment failure at week 48 was non-
compliant with caloric requirement due to religious fasting and
had an HIV RNA of 870 c/mL; confirmatory HIV RNA re-
peated 3 weeks later was 137 c/mL and genotype testing could
not be obtained. Using the VAS, perfect medication adher-
ence over 7 days was reported for 96% (27/28) and 85% (23/
27) of women at weeks 24 and 48, respectively. All 4 women
who reported imperfect ARV adherence at week 48 were
virologically suppressed.
Compliance with caloric intake
At week 48, median caloric intake by food diary was 820 kcal
(n = 21) and by random phone assessment was 677 kcal (n = 26)
(Table 2). Median kcal intake (by food diary) did not change
significantly from baseline (684 kcal, Q1, Q3: 541, 916) to
week 48 (820 kcal; Q1, Q3: 635, 950); median change 102 kcal,
p = .15. Compliance with a ‡400 kcal meal at week 48 was
81% (21 of 26 women) by random phone assessment and
86% (18 of 21 women) by food diary. Compliance with food
diary maintenance was high (86% at weeks 24 and 48). Body
weight remained stable from baseline to week 48 (baseline
and week 48 median weight 84 kg; median change from
baseline 0.0 kg, p = .56). Median intake of macronutrients was
numerically similar at baseline and week 48, and SSB com-
prised 11% and 14% of median total kcal consumed at base-
line and week 48, respectively (Table 2). Consumption of SSB
contributed to approximately one-third of the median carbo-
hydrate content of the participant’s diet at week 48.
Association between virologic suppression
and caloric intake
Women who reported noncompliance with a ‡400 kcal
meal did not experience virologic failure. At week 48, among
women who had both viral load and calorie intake mea-
surement, noncompliance with a ‡400 kcal meal was re-
ported by 10% (2 of 20) and 20% (5 of 25) of women by food
diary and random phone assessment, respectively; all of these
women had HIV RNA levels <50 c/mL. Significant concor-
dance between caloric compliance and viral suppression was
not detected (Food diary kappa: 0, p > .99; Random phone
assessment kappa: -0.07, p > .99).
Lipid profile
Fasting lipid profiles at baseline and week 48 are shown in
Table 3 and Figures 1–3. Women experienced a significant
Table 1. Baseline Characteristics
of the Study Population
n (%) or median
(Q1, Q3)
Race/ethnicity
Black 24 (73)
White 6 (18)
Other 3 (9)
Age (years) 46 (40, 52)
Years since HIV diagnosis 13.1 (8.3, 18.6)
HIV-1 RNA (<50 copies/mL) 33 (100%)
CD4 count (cells/lL) 740 (529, 1006)
Previous ART dose frequency
Once daily 19 (58)
Twice daily 14 (42)
Previous ART regimen
Boosted PI 18 (55)
NNRTI 10 (30)
Other 5 (15)
Body weight (kg) 84 (71, 95)
BMI category
Underweight (<18.5) 1 (3)
Normal (18.5 to <25) 3 (9)
Overweight (25 to <30) 9 (27)
Obese (30+) 20 (61)
Perfect adherence visual analog scale
(7 day run-in period)
32 (97)
ART, antiretroviral treatment; BMI, body mass index; NNRTI,
non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Table 2. Median Caloric and Macronutrient Intake Based on Food Diaries and Random Calls
Food diary Random calls
Baseline (n = 29) Week 24 (n = 28) Week 48 (n = 21) Week 24 (n = 30) Week 48 (n = 26)
Median intake including sugar-sweetened beverages (Q1, Q3)
Total kilo calories 684 (541, 916) 675 (496, 894) 820 (635, 950) 740 (510, 852) 677 (476, 944)
Carbohydrate (g) 78.9 (51.4, 110.8) 78.1 (59.2, 97.4) 92.0 (68.4, 112.5) 74.9 (63.9, 113.1) 58.9 (50.3, 103.3)
Protein (g) 29.4 (22.9, 43.0) 23.0 (15.4, 29.1) 28.1 (24.3, 45.1) 27.8 (19.8, 31.7) 29.9 (19.6, 43.8)
Fat (g) 25.7 (18.0, 39.0) 24.7 (12.3, 37.4) 26.5 (18.1, 37.0) 27.5 (15.4, 35.4) 29.1 (16.4, 44.0)
Median intake excluding sugar-sweetened beverages (Q1, Q3)
Total kilo calories 609 (495, 750) 553 (420, 759) 705 (502, 915) 650 (377, 793) 593 (476, 700)
Carbohydrate (g) 51.6 (39.1, 83.6) 58.1 (50.2, 68.9) 62.0 (47.0, 86.5) 56.2 (28.5, 85.4) 51.9 (38.2, 70.3)
Protein (g) 29.4 (22.7, 43.0) 22.5 (15.4, 29.1) 28.0 (20.5, 36.1) 27.8 (18.8, 31.7) 27.3 (18.8, 43.8)
Fat (g) 25.7 (17.7, 38.8) 24.7 (12.3, 37.1) 26.2 (16.9, 37.0) 25.7 (15.6, 35.4) 28.8 (12.5, 44.0)
decline in total cholesterol (median change -16 mg/dL,
p = .011), triglycerides (median change -21 mg/dL, p = .019),
and high-density lipoprotein (HDL) cholesterol (median
change -8.5 mg/dL, p = .003). Low-density lipoprotein (LDL)
cholesterol remained almost unchanged between baseline and
week 48 (median 1 mg/dL, p = .61). There was also no sig-
nificant change in the ratio of total cholesterol to HDL (median
0.23, p = .11).
Discussion
To our knowledge, this is the first FTC/RPV/TDF switch
study conducted exclusively in HIV-positive women to (1)
describe maintenance of virologic suppression, (2) under-
stand the ability of HIV-positive women to comply with the
dietary requirements of an RPV-containing STR, and (3)
investigate the concordance between medication and caloric
intake and virologic suppression. We demonstrated mainte-
nance of virologic suppression similar to other FTC/RPV/
TDF switch studies with high rates of suppression at weeks
24 and 48 (97% and 96%, respectively) in a population of
women who were predominantly African American.1,2
We found that most (86% by food diary) women were able
to comply with the recommended caloric intake of ‡400 kcal.
We believe that the caloric data obtained in our study is
particularly robust as we (1) employed random phone call
assessment to validate the reported caloric intake obtained
through food diaries and (2) facilitated high compliance with
food diary maintenance through avoidance of diary fatigue.
This is supported by the fact that few women did not return
the food diaries. Notably, women were able to comply with a
400 kcal meal requirement without changing calorie intake.
This likely contributed to the stability of the women’s weight
throughout the duration of the study. As 88% of the women
were overweight or obese at baseline, the lack of weight gain
despite the caloric requirement is a particularly favorable
finding for this ART regimen.
We found no concordance between caloric intake and vi-
rologic suppression. Few women (five through random calls
and two through food diary) reported noncompliance with the
‡400 kcal requirement. Reassuringly all of the women who
were noncompliant with the recommended calorie intake
remained virologically suppressed (HIV RNA <50 c/mL).
While these results are reassuring, it should be noted that a 3-
day food diary may have underestimated the number of times
RPV was taken with less than 400 calories. The 3-day recall
was a median and participants may have been more adherent
to calorie intake when maintaining their diary. That there was
good agreement between random calls and food diary
Table 3. Fasting Lipid Parameters (mg/dL)
Baseline median
(Q1, Q3)
Week 48 median
(Q1, Q3)
Change from
baseline median
(Q1, Q3) p
Total cholesterol 181 (168, 203) 160 (141, 188) -16.0 (-38.0, -6.0) .011
n = 31 n = 24 n = 22
LDL cholesterol 101 (88, 123) 98 (77, 130) +1.0 (-23.0, +14.0) .61
n = 30 n = 23 n = 20
HDL cholesterol 54 (45, 70) 50 (39, 54) -8.5 (-17.0, -1.0) .003
n = 31 n = 24 n = 22
Triglycerides 105 (73, 188) 95 (52, 118) -21.0 (-49.0, +2.0) .019
n = 31 n = 23 n = 21
Cholesterol:HDL ratio 3.50 (2.59, 4.35) 3.37 (2.85, 4.63) +0.23 (-0.17, +0.54) .11
n = 31 n = 24 n = 22
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
FIG. 1. Total cholesterol at baseline and week 48.
FIG. 2. Low-density lipoprotein (LDL) cholesterol at
baseline and week 48.
suggests that women were not more adherent during re-
cording period.
We noted improvements in some of the fasting lipid
components after switching to FTC/RPV/TDF. In keeping
with other FTC/RPV/TDF switch studies, women had sig-
nificant decreases in total cholesterol (median decrease
16 mg/dL), HDL cholesterol (median decrease 8.5 mg/dL),
and triglycerides (median decrease 21 mg/dL). However, we
differ from other studies, in that women in our study did not
experience any change in LDL cholesterol (median increase
1 mg/dL).1,2 This study population had a high proportion
(88%) of overweight/obese participants with the concomitant
comorbid risks of diabetes, cardiovascular disease, and
stroke. Therefore, any therapy that confers potentially ben-
eficial lipid changes is worthy of consideration.
A significant strength of our study might also contribute
to a limitation as we only enrolled women, and in doing so
limited the generalizability of the study results. However, we
specifically chose a women-only study population due to the
potential benefits that this regimen could confer on women,
namely pregnancy category and lack of interaction with oral
contraceptives, and the fact that there were limited data from
clinical trials in this population. Other considerations that
might limit the generalizability of study results are (1) small
sample size, which can once again be attributed to the goal of
enrolling only women, and (2) the women were enrolled from
a single clinic population. The open-label design of this study
might have contributed to bias, both from the clinical trial
team and the patient.
Reasons for ART regimen switching in patients who are
virologically suppressed are multifactorial. The current De-
partment of Health and Human Services guidelines suggest
that among the strategies for switching, there is good sup-
porting evidence for within-class switches from EFV to
RPV and from a PI-based regiment to RPV.7 Our study
results are in agreement with these earlier studies. We
demonstrated that compliance with the food requirement
that some might consider a hindrance was easily achievable
in this population. Additional reasons that favor using FTC/
RPV/TDF are the improvements in fasting lipid profile and
the lack of weight gain in our participants. We believe that
once-daily FTC/RPV/TDF represents a convenient and ef-
fective option for women and the calorie intake required is
readily achievable.
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FIG. 3. Total cholesterol to high-density lipoprotein
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